SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors aggressively accumulate ahead of anticipated institutional partnerships and the potential passing of the Clarity Act. While some community members remain skeptical, many are focused on the project's utility in the agentic AI economy and its ongoing infrastructure integration with major financial networks.

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending as investors monitor ongoing discussions with the FDA regarding the OLC manufacturing deficiency, which the community views as a critical path toward the June 29 PDUFA date. Discussions are heavily focused on the company's ability to maintain a clear regulatory timeline while balancing cash reserves and shareholder concerns about equity dilution.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton Network is gaining significant traction as a key infrastructure project for institutional finance, with major global payment companies joining as validators. The community is actively discussing its long-term potential in tokenized asset settlement, while closely monitoring token supply dynamics and exchange listing momentum.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant attention as investors anticipate its expansion to the Ethereum mainnet and a potential broader market recovery. The community is actively discussing its role as a key liquidity hub on the Base chain, with many debating the sustainability of its token emissions model versus its potential for explosive growth.

Allora is a decentralized intelligence network that makes artificial intelligence more adaptive, collaborative, and efficient. The platform combines and coordinates thousands of specialized AI models in real time to produce superior inferences for users and applications. By enabling anyone to contribute models, data, or validation, Allora creates a self-improving market for intelligence that powers agents, DeFi systems, and AI applications across chains.

Allora

Allora is generating significant interest as traders debate its momentum and potential for a short squeeze following recent exchange volatility. Community sentiment remains polarized, with many highlighting the coin's low circulating supply and upcoming project announcements as key drivers for potential upside.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is attracting intense investor interest as market participants speculate on potential acquisition interest and a short squeeze triggered by S&P index inclusion, while analysts highlight improved profitability and platform growth as core catalysts. The community is actively debating the company's valuation, questioning if the platform's long-term advertising and subscription momentum justifies a major breakout from current price levels.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending following positive registrational trial data for its CAR-T therapy miv-cel in Stiff Person Syndrome, with investors actively discussing its potential as a first-in-class treatment and a primary target for future M&A. The community is focused on the therapy's ability to drive durable, drug-free remission in refractory autoimmune patients, while also monitoring the company's capital allocation and broader pipeline expansion.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is facing intense scrutiny as investors debate its long-term viability amid ongoing price volatility, with community sentiment deeply divided between those betting on its technical potential and others dismissing it as a failing project. Discussions are heavily focused on the impact of upcoming tokenomics shifts, the progress of Polkadot 2.0, and whether the network can generate sufficient real-world adoption to trigger a meaningful recovery.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as the community highlights the recent v4 launch and the successful implementation of a revenue-sharing model that distributes decentralized GPU compute earnings to node runners and stakers. Investors are focused on the project's low market cap and the high percentage of supply locked in long-term staking, viewing it as a significant opportunity within the AI infrastructure and agentic narrative.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a late-breaking abstract presentation of Phase 2 axSpA data at the EULAR congress, which the community is interpreting as a 'best-in-class' signal. Investors are actively discussing the upcoming 52-week VELA trial results and the company's participation in the Goldman Sachs Healthcare Conference as critical catalysts that could drive a significant re-rating or trigger acquisition interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
